GlassScriptPhysician profile
Kimberly Gatzimos
NPI 1174510127
$6,487.94
in general payments reported to CMS, 2019-2025
51 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,943 · 2020: $1,447 · 2021: $1,711 · 2022: $112 · 2024: $116 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $871.29 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $553.28 | 2019-2021 | |
| Lilly USA, LLC | $460.63 | 2019-2021 | |
| Amgen INC. | $390.13 | 2019-2021 | |
| Allergan, INC. | $381.14 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $380.14 | 2019-2021 | |
| Abbvie INC. | $364.67 | 2021-2022 | |
| Astellas Pharma US INC | $318.39 | 2019-2022 | |
| Pfizer INC. | $270.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $261.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $205.84 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $199.29 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.39 | 2019-2021 | |
| Radius Health, INC. | $138.56 | 2020-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.82 | 2019-2025 | Jardiance |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Gatzimos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.